Non-muscle Invasive Bladder Cancer (NMIBC) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market and Companies by DelveInsight

(Albany, USA) DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Non-muscle Invasive Bladder Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Non-muscle Invasive Bladder Cancer Pipeline Outlook - https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Non-muscle Invasive Bladder Cancer Pipeline Report
• August 2024:- Janssen Research & Development LLC- A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guerin (BCG) and Recurred With High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy. The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guerin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
• August 2024:- Protara Therapeutics- A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer. TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC ( plus-minus Ta/T1).
• DelveInsight's Non-muscle Invasive Bladder Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Non-muscle Invasive Bladder Cancer treatment.
• The leading Non-muscle Invasive Bladder Cancer Companies such as Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.
• Promising Non-muscle Invasive Bladder Cancer Therapies such as TAR-200, Mitomycin C, Gemcitabine, Avelumab, RC48-ADC, and others.

Stay ahead with the most recent pipeline outlook for Non-muscle Invasive Bladder Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-muscle Invasive Bladder Cancer Treatment Drugs - https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Non Muscle Invasive Bladder Cancer Emerging Drugs
• TAR-200: TARIS Biomedical
TAR-200 is an investigational targeted releasing system enabling controlled release of gemcitabine into the bladder, sustaining local drug exposure for weeks at a time. The safety and efficacy of TAR-200 are being evaluated in Phase II and Phase III studies in patients with muscle-invasive bladder cancer in SunRISe-2 and SunRISe-4 and NMIBC in SunRISe-1 and SunRISe-3. Currently, the drug is in Phase III stage of its clinical trial for the treatment of non muscle invasive bladder cancer.

• VAX 014: Vaxiion Therapeutics
VAX014 is a novel rBMC-based oncolytic immunotherapy designed to have distinct advantages over traditional and emerging oncolytic virotherapies. VAX014's ability to specifically target both alpha3beta1(31) and alpha5beta1 (51) integrins facilitates broad spectrum activity against various solid tumor types because these two integrin family members are clinically validated as being selectively expressed or overexpressed in a wide variety of solid tumor indications (and most mouse models). Currently, the drug is in the Phase I stage of its development for the treatment of Non muscle-invasive bladder cancer.

• SIM0237: Simcere Pharmaceutical Group
SIM0237 is an anti-PD-L1 monoclonal antibody fused with potency-reduced IL-15/IL-15R sushi domain developed in-house by utilizing Simcere Zaiming's protein engineering platform. As a bifunctional protein, the compound can block the PD-1/PD-L1 immunosuppressive pathway via binding to PD-L1 and activate the immune system through its IL-15 part, thus playing a synergistic role of relieving immunosuppression and boosting the immune activation to exhibit antitumor effect. The attenuated IL-15 part of SIM0237 increases MTD and avoids overstimulation and accompanied anergy of NK and CD8+ T cells. In the meantime, fusion of attenuated IL-15 to full anti-PD-L1 mAb further enhances the half-life of attenuated IL-15 and delivers IL-15 directly to the tumor microenvironment avoiding notorious CRS toxicity induced by systemic IL-15 exposure. Currently, the drug is in Phase I stage of its clinical trial for the treatment of non muscle invasive bladder cancer.

Explore groundbreaking therapies and clinical trials in the Non-muscle Invasive Bladder Cancer Pipeline. Access DelveInsight's detailed report now! @ New Non-muscle Invasive Bladder Cancer Drugs - https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Non-muscle Invasive Bladder Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Non-muscle Invasive Bladder Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non-muscle Invasive Bladder Cancer Market Drivers and Barriers - https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Non-muscle Invasive Bladder Cancer Pipeline Report
• Coverage- Global
• Non-muscle Invasive Bladder Cancer Companies- Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.
• Non-muscle Invasive Bladder Cancer Therapies- TAR-200, Mitomycin C, Gemcitabine, Avelumab, RC48-ADC, and others.
• Non-muscle Invasive Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-muscle Invasive Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Non-muscle Invasive Bladder Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Non-muscle Invasive Bladder Cancer Companies, Key Products and Unmet Needs - https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
• Introduction
• Executive Summary
• Non Muscle Invasive Bladder Cancer: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Non Muscle Invasive Bladder Cancer- DelveInsight's Analytical Perspective
• Late Stage Products (Phase III)
• TAR-200: TARIS Biomedical
• Drug profiles in the detailed report.....
• Mid Stage Products (Phase II)
• Drug name: Company name
• Drug profiles in the detailed report.....
• Early Stage Products (Phase I)
• VAX 014: Vaxiion Therapeutics
• Drug profiles in the detailed report.....
• Preclinical and Discovery Stage Products
• Drug Name: Company Name
• Drug profiles in the detailed report.....
• Inactive Products
• Non Muscle Invasive Bladder Cancer Key Companies
• Non Muscle Invasive Bladder Cancer Key Products
• Non Muscle Invasive Bladder Cancer- Unmet Needs
• Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
• Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
• Non Muscle Invasive Bladder Cancer Analyst Views
• Non Muscle Invasive Bladder Cancer Key Companies
• Appendix

Trending Reports:
• Calcinosis Cutis Market: https://www.delveinsight.com/report-store/calcinosis-cutis-market
• Aicardi-goutières Syndrome Market: https://www.delveinsight.com/report-store/aicardi-goutieres-syndrome-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-epidemiology-forecast
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Hemophilia With Inhibitor Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Chronic Gout Market: https://www.delveinsight.com/report-store/chronic-gout-market
• Myocardial Infarction Market: https://www.delveinsight.com/report-store/myocardial-infarction-market
• Critical Limb Ischemia Market: https://www.delveinsight.com/report-store/critical-limb-ischemia-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Beta Thalassemia Market: https://www.delveinsight.com/report-store/beta-thalassemia-market
• Chronic Refractory Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Eosinophilic Asthma Market: https://www.delveinsight.com/report-store/eosinophilic-asthma-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/sample-request/familial-primary-pulmonary-hypertension-market
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/trigeminal-neuralgia-market
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Corneal Ulcer Market: https://www.delveinsight.com/report-store/corneal-ulcer-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.